Our lead program is advancing through formulation development toward a first-in-human pilot study, with a clear regulatory path built on well-characterized active ingredients.
Key milestones in our path from formulation to clinical proof-of-concept.
Final formulation selection incorporating permeation-enhanced drug delivery profile with confirmed stability.
Institutional review board approval for the SATORI pilot study, enabling first-in-human clinical evaluation.
GMP-compliant clinical batch manufacturing and release testing completed for pilot trial supply.
Enrollment of first patient in the SATORI pilot trial, representing a transformational proof-of-concept milestone.